In a nutshell The study evaluated outcomes of ixazomib (Ninlaro) as a maintenance therapy in patients with newly diagnosed multiple myeloma (MM) not undergoing autologous stem cell transplantation (ASCT). The main finding was that ixazomib maintenance safely improved progression-free survival (PFS) in such patients. Some background...
Read More
In a nutshell This trial was carried out to examine the effectiveness and safety of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone (Decadron) in relapsed or refractory (unresponsive) multiple myeloma (MM). The authors found that there was an improved survival in these patients in the long-term. Some...
Read More
In a nutshell This trial was carried out to examine the long-term safety and effectiveness of daratumumab (Darzalex) plus bortezomib (Velcade) and dexamethasone (Dexasone) in patients with previously treated multiple myeloma (MM). The authors concluded that after 3-years this treatment maintained benefit and...
Read More
In a nutshell This trial was carried out to look at how safe and effective the addition of daratumumab (Darzalex) would be to the RVd regimen involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) in the treatment of patients with newly diagnosed multiple myeloma (MM). The...
Read More
In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...
Read More
In a nutshell This study assessed the use of daratumumab (Darzalex) plus bortezomib (Velcade)/dexamethasone (Dexasone) or D-Vd versus bortezomib/dexamethasone (Vd) alone as a treatment for patients with high-risk multiple myeloma (MM). The authors found that D-Vd was effective and showed good tolerability...
Read More
In a nutshell This study is being carried out to examine whether KRD including carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Decadron) with or without daratumumab (Darzalex) is safe and effective in the treatment of multiple myeloma (MM). The main outcome to be measured is the measurable residual...
Read More
In a nutshell The study evaluated outcomes of the combination of carfilzomib (Kyprolis; K), dexamethasone (Decadron; d), and daratumumab (Darzalex; D) in patients with relapsed or refractory (r/r) multiple myeloma (MM). The authors found that KdD was safe and effective to improve progression-free survival (PFS) in such patients compared to...
Read More
Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...
Read More
In a nutshell This study investigated which was the best treatment approach before and after stem cell transplantation (SCT) for patients newly diagnosed with multiple myeloma (MM). The results showed that patients’ survival was better with CRD (cyclophosphamide, lenalidomide, and dexamethasone) chemotherapy than with CTD (cyclophosphamide,...
Read More
In a nutshell The study evaluated long-term outcomes of RVD involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) and risk-based maintenance therapy in patients with newly diagnosed multiple myeloma (MM). The authors found this approach to be beneficial for survival in a large group of patients. Some background RVD...
Read More
In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...
Read More
